Video Editing for Medical Device Companies
content that stays inside your cleared indication and survives regulatory review

In most verticals, exaggerated marketing language is a brand-tone problem. In medical devices, it's a regulatory one — the FDA and equivalent bodies treat promotional claims that exceed a device's cleared or approved indication for use as a potential violation, regardless of whether the underlying science is sound. A device cleared for one specific diagnostic use cannot be marketed as effective for an adjacent use, even if physicians are informally using it that way off-label, and language implying superiority or outcomes beyond what's in the labeling needs specific substantiation most companies aren't positioned to produce for a social clip.

We treat every script and caption as needing a pass against the device's current indication for use before it ships, and we flag anything that reads as implying an unapproved use, a comparative superiority claim without citation, or language a regulatory affairs reviewer would likely reject. We are not a substitute for your regulatory affairs or legal review — that sign-off needs to happen on your side before anything goes to external audiences — but we aim to hand you a draft that's already been screened against the obvious failure modes rather than one that bounces back from RA with a full rewrite.

Key opinion leader interviews carry outsized credibility in this category — a respected physician speaking candidly about a device or diagnostic tool does more to move a hospital procurement committee or a peer physician's opinion than almost any polished corporate video could. The catch is that KOL time is scarce and usually captured in short, imperfect windows: a ten-minute slot at a conference, a hallway conversation between sessions, a quick call squeezed into a physician's clinical schedule.

This means the editing approach has to extract maximum value from limited, sometimes messy raw footage — background noise, inconsistent lighting, an interview that gets cut short mid-thought. We prioritize getting the clearest possible clinical statement out of what's actually usable rather than needing pristine studio conditions, and we typically cut one KOL session into several distinct pieces (a credibility-building short clip, a longer sales-enablement segment, a quote graphic for slide decks) to get full mileage from a single scarce interview.

Most of a med device company's highest-value raw footage gets captured in concentrated bursts around two to four major medical conferences a year, rather than trickling in steadily like it would for a typical B2B company. This creates a distinct production rhythm: intense capture and rapid-turnaround needs during and immediately after the event, followed by a longer stretch of editing that same footage into a distribution schedule spanning the following two to four months, since attention and content needs don't stop the week after the conference ends.

We plan editing capacity around this in advance — a heavier turnaround push in the days immediately following a conference for time-sensitive recap and social content, then a steadier cadence for the following months pulling from the same footage library for sales-enablement, LinkedIn, and internal training use. Companies that only think about content in the two weeks after a conference and let the rest of the footage sit unused are leaving a substantial amount of value on the table from footage they already paid to capture.

Med device companies typically need to serve at least three distinct audiences — practicing physicians and hospital buying committees, investors and analysts, and prospective hires in a competitive technical hiring market — and the instinct to cut one video into slightly different lengths for each audience usually underperforms compared to building genuinely separate messaging tracks. A physician evaluating clinical evidence needs specificity and credibility signals; an investor wants a growth and market narrative; a candidate wants to understand the mission and the team culture.

We typically keep these tracks editorially distinct even when they're drawn from the same underlying footage — the same KOL interview might supply a data-forward clip for physician audiences and a completely different, more narrative-driven clip for an investor update, cut with different pacing, different supporting graphics, and different calls to action.

While public-facing social content gets most of the planning attention, the field sales team's need for short, current, easily shareable clips — a two-minute procedure overview, a physician testimonial clip they can attach to an email, a competitive positioning explainer — often produces a more direct and measurable business impact than broader brand awareness content, precisely because it shortens a specific, identifiable sales conversation. Sales teams in this category frequently report back that a well-cut clip closed a specific piece of a deal in a way that's much harder to trace for general brand content.

We recommend building a standing sales-enablement request line into the monthly production plan, separate from the public content calendar, so field reps have a place to request specific clips ahead of a big procurement pitch rather than only getting new material after the next conference cycle.

Device and diagnostics marketing generally centers on physicians and clinical evidence rather than patient stories, but when patient footage is used — a recovery story, a diagnostic journey — the consent and review requirements typically go beyond a standard media release given the added regulatory sensitivity around implying a specific outcome tied to device use. We recommend involving your legal and regulatory teams specifically on any patient-facing content before it's filmed, not just before it's published, since the framing of the interview itself needs to avoid inviting outcome claims the device's labeling doesn't support.

In practice, most companies in this category get more marketing value from physician and KOL-centered content than from patient stories, given how much scrutiny patient outcome content invites — we typically suggest treating patient content as an occasional, carefully reviewed addition rather than a content pillar.

Most device companies land on SURGE at $2,995/mo to cover the mixed workload of physician-facing content, sales-enablement clips and periodic congress recap production, with volume flexing higher around major conference months. Companies with a heavier trade-show calendar or a larger field sales team requesting custom clips often move to TAKEOVER. We suggest planning your first engagement around your next scheduled conference so we can test the rapid post-event turnaround workflow specifically, rather than starting on a quiet month with no fresh footage to work from.

Build the regulatory review step into your own internal timeline expectations from the start — we build a review buffer into our turnaround estimate, but the larger schedule risk is usually how long your internal RA sign-off takes, which is worth clarifying with that team before committing to a monthly cadence.

If your regulatory affairs or legal team hasn't yet established even an informal fast-track process for reviewing short-form marketing content, a monthly retainer will likely produce a backlog of unpublished clips waiting on sign-off rather than a working content pipeline. It's worth establishing that internal review pathway, even a lightweight one, before committing to a steady production cadence.

You're also not the right fit yet if you don't have any KOL or physician relationships willing to be filmed — device marketing without credible clinical voices attached tends to read as generic corporate content to the physician and procurement audiences that actually matter here, and there's no substitute for that credibility layer in this category.